TY - JOUR
T1 - Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy
AU - De Bona, Anna
AU - Galli, Laura
AU - Gallotta, Giulia
AU - Guzzo, Aurelia
AU - Alagna, Laura
AU - Lazzarin, Adriano
AU - Uberti-Foppa, Caterina
PY - 2007/7
Y1 - 2007/7
N2 - This is a retrospective longitudinal follow-up study of 25 HIV/HCV positive cirrhotic patients not responding to peg-IFN plus ribavirin, and 25 untreated controls matched for age (±5 years), gender and Child-Pugh score. The primary endpoint of the study was the incidence of cirrhosis progression (CP) defined as the occurrence of at least one of the following events: death, ascites, jaundice, encephalopathy, gastrointestinal bleeding and hepatocellular carcinoma (HCC). During the median follow-up of 54 months (34-89), four treated (16%) and 13 untreated patients (52%) experienced CP (p=0.02). Poisson's regression model showed that the independent predictors of CP were Peg-IFN therapy (p=0.016), positive HIV-RNA (p=0.024), and altered ALP values (p=0.012). Peg-IFN therapy seems to slow down the rate of cirrhosis progression also in HIV/HCV co-infected patients nonresponders to anti-HCV therapy, in comparison with untreated patients.
AB - This is a retrospective longitudinal follow-up study of 25 HIV/HCV positive cirrhotic patients not responding to peg-IFN plus ribavirin, and 25 untreated controls matched for age (±5 years), gender and Child-Pugh score. The primary endpoint of the study was the incidence of cirrhosis progression (CP) defined as the occurrence of at least one of the following events: death, ascites, jaundice, encephalopathy, gastrointestinal bleeding and hepatocellular carcinoma (HCC). During the median follow-up of 54 months (34-89), four treated (16%) and 13 untreated patients (52%) experienced CP (p=0.02). Poisson's regression model showed that the independent predictors of CP were Peg-IFN therapy (p=0.016), positive HIV-RNA (p=0.024), and altered ALP values (p=0.012). Peg-IFN therapy seems to slow down the rate of cirrhosis progression also in HIV/HCV co-infected patients nonresponders to anti-HCV therapy, in comparison with untreated patients.
KW - Cirrhosis progression
KW - HIV/HCV co-infection
KW - Non-responders
KW - Peg-IFN
UR - http://www.scopus.com/inward/record.url?scp=34547934022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547934022&partnerID=8YFLogxK
M3 - Article
C2 - 17802905
AN - SCOPUS:34547934022
VL - 30
SP - 259
EP - 264
JO - New Microbiologica
JF - New Microbiologica
SN - 1121-7138
IS - 3
ER -